ASSESSMENT OF PAI-1 AND PLASMINOGEN IMBALANCE AND THEIR ROLE IN ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDER ANTICOAGULANT THERAPY

Abstract

Acute coronary syndrome (ACS) is caused by acute thrombus formation on a disrupted atherosclerotic plaque and is closely associated with endothelial dysfunction, inflammation, and activation of the coagulation cascade. Anticoagulant therapy is an essential component of ACS management; however, clinical outcomes depend not only on suppression of coagulation but also on the functional integrity of the fibrinolytic system. Recent evidence suggests that persistent hypofibrinolysis, driven by increased plasminogen activator inhibitor-1 (PAI-1), may limit the effectiveness of anticoagulant therapy. PAI-1 is synthesized by endothelial cells, platelets, and adipose tissue and represents a key mediator linking endothelial dysfunction, inflammation, and thrombosis. Elevated PAI-1 suppresses plasmin generation and stabilizes thrombus structure. Plasminogen, the central substrate of fibrinolysis, may increase as a compensatory response to fibrinolytic inhibition. However, in the presence of excessive PAI-1 activity, elevated plasminogen does not translate into effective fibrin degradation. Thus, the imbalance between PAI-1 and plasminogen may represent a critical mechanism of residual thrombotic risk in ACS, even under anticoagulant therapy.

PDF